Neoadjuvant nivolumab + chemotherapy improved pathological complete response rate regardless the stage of NSCLC

New analyses of CheckMate-816 show that neoadjuvant nivolumab in combination with platinum-doublet chemotherapy did not compromise tumor resection outcome and significantly improved pathological complete response rate compared to chemotherapy alone in patients with resectable non-small cell lung cancer.